In this review:
Polatuzumab vedotin combination bests standard of care in DLBCL
R-mini-CHOP + ibrutinib extends PFS in elderly patients with DLBCL
BELINDA: tisagenlecleucel fails to prolong EFS for aggressive NHL
Mosunetuzumab elicits deep and durable remissions in pre-treated RR FL
Prophylactic high-dose methotrexate does not reduce the risk for CNS relapse
ctDNA shows promise as biomarker in CNS lymphoma
Enhanced lymphodepletion may improve efficacy of allogeneic CAR T therapy
Salvage BBV + transplant promising for RR T cell lymphoma
Escalated BPDac effective and less toxic than eBPP
MAGNIFY: Lenalidomide + rituximab induction active and safe in RR NHL
Please login below to download this issue (PDF)